Melanotan II: What the Research Actually Shows

A Comprehensive Evidence Review — Melanocortin Receptor Biology, Tanning Mechanism, Libido Effects, and the Safety Profile That Matters

In the summer of 1996, a researcher at the University of Arizona conducting early human trials of a synthetic tanning peptide experienced an eight-hour erection that required emergency medical treatment. He had injected himself with Melanotan II — a compound developed to induce melanin production and protect against UV damage — and had not been expecting what happened next. That single unexpected pharmacological event redirected a tanning research program, seeded a new area of sexual medicine, and eventually led to the FDA approval of bremelanotide (PT-141) two decades later. Melanotan II may be the only compound in peptide research where an accidental side effect in an unauthorized self-experiment directly produced an FDA-approved drug.

Melanotan II (MT-II) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) developed by Victor Hruby and colleagues at the University of Arizona beginning in the late 1980s. The original goal was pharmacological tanning — a way to induce the skin’s natural UV-protective melanin response without requiring UV radiation exposure, thereby reducing skin cancer risk. MT-II achieved this through potent activation of MC1R (melanocortin receptor 1), the primary receptor governing melanogenesis in melanocytes. What the researchers did not anticipate was that MT-II’s non-selective binding profile extended well beyond MC1R — it also activates MC3R, MC4R, and MC5R, receptors distributed throughout the brain and peripheral tissues with functions entirely unrelated to pigmentation.

This non-selectivity is the key to understanding MT-II: it is simultaneously a tanning agent, a potent libido and sexual arousal stimulant, an appetite suppressant, and a compound with cardiovascular activity — all from the same molecule activating different receptors in different tissues. Each of these effects is mechanistically real. Each comes with its own evidence base, its own risk profile, and its own reason to be evaluated independently rather than as a package. The community that uses MT-II primarily for tanning is having a different pharmacological experience than the community using it for sexual effects, though the compound they are injecting is identical.

MT-II is not FDA-approved for any indication. It has never been submitted for approval. It exists in a regulatory grey zone — widely available from peptide suppliers as a research chemical, actively used by a substantial self-experimentation community, but without the pharmaceutical-grade manufacturing controls, clinical safety monitoring, or evidence base that approval would require. The compounds that learned from MT-II — afamelanotide (FDA-approved 2019 for erythropoietic protoporphyria, MC1R-selective) and bremelanotide/PT-141 (FDA-approved 2019 for HSDD, MC3R/MC4R-selective) — exist precisely because their developers isolated specific aspects of MT-II’s pharmacology and subjected them to rigorous clinical development. MT-II itself remains the unrefined parent from which those refined compounds were derived.

What Is Melanotan II?

Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide cleaved from the proopiomelanocortin (POMC) precursor protein in the pituitary gland and hypothalamus. The native α-MSH sequence is a linear 13-amino acid peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) with a short half-life — approximately 30 minutes in circulation — that limits its pharmacological utility as a drug candidate. Melanotan II was engineered by Hruby’s group to address this limitation through two strategic modifications: a norleucine substitution at position 4 (replacing methionine, which is susceptible to oxidation) and a D-phenylalanine substitution at position 7 (improving receptor binding affinity and metabolic stability). The peptide was further cyclized through a lactam bridge between the lysine and aspartate side chains, converting the linear structure into a conformationally constrained ring that dramatically extends biological activity. The resulting molecule is approximately 10 times more potent than α-MSH at melanocortin receptors and has a substantially longer effective half-life.

These modifications that made MT-II a more effective pharmacological tool also made it less selective. Native α-MSH has modest preferential activity at MC1R under physiological conditions. The cyclic, conformationally constrained MT-II structure allows tight binding across all melanocortin receptor subtypes — MC1R, MC3R, MC4R, and MC5R — without meaningful discrimination between them. This pan-agonist profile is what makes MT-II simultaneously effective at tanning (MC1R), libido enhancement (MC3R/MC4R), and other systemic effects — and what makes it fundamentally different from both afamelanotide (engineered for MC1R selectivity) and PT-141 (engineered to minimize MC1R while retaining MC3R/MC4R activity).

---

Origins: From Tanning Research to Accidental Discovery

The University of Arizona tanning peptide program began with a straightforward hypothesis: melanin provides the most effective protection against UV-induced skin damage, and the skin already has a mechanism to produce it (the melanocortin system). A pharmacological trigger for melanin production — delivered before UV exposure rather than in response to it — could theoretically produce photoprotective tanning without the UV damage that triggers it. This would be particularly valuable for patients with conditions like erythropoietic protoporphyria (EPP), where even minimal sun exposure causes severe pain and skin damage, and for reducing skin cancer incidence more broadly.

Victor Hruby’s medicinal chemistry group synthesized a series of α-MSH analogs through the 1980s, screening for compounds with enhanced potency and stability. MT-II (originally designated [Nle4, D-Phe7]-α-MSH) emerged as the lead compound by the early 1990s based on its substantially enhanced receptor binding affinity and extended half-life. The compound was licensed to Competitive Technologies, Inc. and clinical development began under that entity, later transferred to Palatin Technologies.

The pivotal event occurred during Phase I dose-escalation safety trials in the mid-1990s. A trial participant — widely reported to have been Norman Levine, a University of Arizona dermatologist involved in the research — self-administered a higher-than-protocol dose and experienced prolonged, spontaneous penile erection that required emergency treatment. The erection lasted approximately eight hours. This was not a placebo response, a vascular effect, or an expected pharmacological event — it was direct central nervous system activation through the MC3R and MC4R receptors, which were not yet fully characterized in their role in sexual function at the time of the study. The clinical trial reports noted the finding, published it, and the research program bifurcated: one track continued developing MC1R-selective tanning/photoprotection compounds (eventually becoming afamelanotide), and another began investigating the MC3R/MC4R sexual arousal effects (eventually becoming PT-141/bremelanotide).

MT-II itself — the original non-selective compound — was never taken through full clinical development for either indication. Its non-selectivity made it less attractive than compounds that could be developed for a specific indication with a cleaner receptor profile and more predictable side effect burden. It entered the grey market research chemical supply chain as a consequence, where it has been widely available and used ever since.

---

The Melanocortin Receptor System

The melanocortin system consists of five G-protein-coupled receptors (MC1R through MC5R), their endogenous agonist ligands (ACTH and the MSH peptides, all derived from POMC), and their endogenous antagonists (agouti signaling protein and agouti-related protein). The distribution and function of each receptor subtype is distinct, which is why non-selective agonism like MT-II produces such diverse physiological effects:

Understanding this receptor map makes it immediately clear why MT-II produces the side effect profile it does: the nausea and facial flushing are autonomic effects mediated primarily by MC4R in the brainstem and hypothalamus; the appetite suppression is MC3R and MC4R hypothalamic activity; the sexual arousal and erection are MC3R and MC4R effects in the limbic system and spinal cord; the skin darkening is MC1R activation in melanocytes. Each symptom is a predictable, mechanistically explained consequence of activating a specific receptor subtype — not a random or idiosyncratic event.

---

Tanning Mechanism: MC1R and Melanogenesis

MT-II’s tanning effect operates through the well-characterized MC1R-cAMP-MITF-tyrosinase pathway. When MT-II binds MC1R on epidermal melanocytes, it activates adenylyl cyclase through Gαs coupling, increasing intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element binding protein). Activated CREB upregulates MITF (microphthalmia-associated transcription factor), the master melanocyte transcription factor that controls expression of tyrosinase, TYRP1, TYRP2, and other enzymes in the eumelanin biosynthesis pathway. The net result is increased production of eumelanin — the brown-black melanin pigment that provides UV photoprotection — rather than phaeomelanin (the red-yellow pigment associated with lower photoprotection).

This mechanism is essentially identical to what happens when UV light triggers natural tanning — UV-induced DNA damage in keratinocytes causes p53 activation and subsequent POMC upregulation, releasing α-MSH that acts on melanocytes through the same MC1R-cAMP-MITF pathway. MT-II bypasses the UV trigger entirely, activating the same downstream pathway pharmacologically. The result is melanin synthesis without the UV-induced DNA damage that causes it under natural conditions — which was the original therapeutic goal for photoprotective tanning.

The tanning effect requires some minimal UV exposure in most individuals to observe clinical skin darkening — MT-II appears to prime and amplify the melanogenic response rather than completely replacing UV as a trigger, though significant tanning is reported with minimal UV by many users. Individuals with MC1R loss-of-function variants (common in red-haired, fair-skinned individuals of Northern European ancestry) may have reduced tanning response to MT-II because their MC1R cannot be fully activated regardless of agonist concentration — this is the same reason those individuals don’t tan well from UV exposure either.

---

Libido and Sexual Arousal: MC3R and MC4R

The sexual effects of MT-II — and by extension of PT-141, which was specifically developed to capitalize on them — are mediated through MC3R and MC4R in the central nervous system. This central mechanism is what distinguishes melanocortin-mediated sexual arousal from the vascular mechanism of PDE5 inhibitors like sildenafil and tadalafil. PDE5 inhibitors work peripherally by blocking cGMP degradation in penile vascular smooth muscle, improving blood flow to an already-aroused penis. MC3R/MC4R agonists work centrally by activating desire and arousal pathways in the hypothalamus and limbic system — the neural circuits that generate sexual motivation, not just the vascular response to it.

MC4R in the paraventricular nucleus of the hypothalamus is the primary mediator of the penile erectile response through melanocortin agonism. Activation of MC4R in this region triggers downstream oxytocin release and stimulation of the medial preoptic area (MPOA), a region critical to male sexual behavior. This hypothalamic-to-spinal signaling cascade activates the sacral parasympathetic pathway that governs erection — through a neural, not vascular, initial mechanism. The erection that results is therefore qualitatively different from a PDE5-facilitated erection: it originates from central desire activation rather than peripheral vascular facilitation, which is why it can occur in men with significant vascular disease and why it is accompanied by genuine arousal rather than just mechanical response.

In women, MC4R activation in the hypothalamus and limbic system produces increased sexual arousal and genital vasocongestion. The PT-141 development program demonstrated these effects in women with hypoactive sexual desire disorder in the clinical trials that led to FDA approval — making this the best-characterized application of the MC3R/MC4R sexual mechanism in a controlled trial setting. MT-II’s effects in women are mechanistically the same but have been less formally characterized because MT-II itself was never taken through a controlled women’s sexual health trial.

---

MT-II vs Afamelanotide vs PT-141: The Selectivity Story

The three melanocortin compounds most relevant to researchers can be understood as variations along a selectivity spectrum. MT-II is the broadest — a pan-agonist that activates all four pharmacologically relevant receptor subtypes (MC1R, MC3R, MC4R, MC5R) with relatively similar potency. The two FDA-approved descendants were developed by selecting for specific endpoints and engineering away from the others.

The practical implication of this comparison: if the goal is tanning for photoprotection, afamelanotide is the evidence-backed, FDA-approved, monitored option — but it is only accessible to EPP patients through the approved indication. If the goal is sexual arousal, PT-141 is the evidence-backed, FDA-approved option — accessible by prescription for women with HSDD and off-label in men. MT-II provides both effects simultaneously but with neither the clinical purity nor the quality controls of the approved compounds, and without the pharmacovigilance safety monitoring that prescription use provides.

---

Key Research and Studies

Early Phase I Human Tanning Trials

Dorr et al. (1996) published the first controlled human trial of MT-II for tanning in the Archives of Dermatology. The study enrolled fair-skinned volunteers and administered escalating SC doses of MT-II while monitoring skin pigmentation, side effects, and safety parameters. Results confirmed dose-dependent tanning with objective melanin measurement increases. The adverse effects profile that became the signature of MT-II research was clearly established: nausea occurred in most subjects at effective tanning doses, facial flushing was common, and spontaneous penile erections in male subjects were reported — the clinical documentation of the event that redirected the research program. This study remains the primary published human Phase I data for MT-II and is frequently cited as the foundation of both the tanning and sexual medicine research directions.

Erectile Function Studies

Wessells et al. (1998 and 2000) conducted the first controlled studies of MT-II specifically for erectile dysfunction, following up on the Dorr Phase I observations. Using rigorous pharmacological endpoints including RigiScan monitoring, they demonstrated that SC MT-II produced significantly greater erectile activity than placebo in men with both psychogenic and organic erectile dysfunction. These are the most directly relevant published controlled data for MT-II’s sexual effects in humans — small, early-phase studies rather than definitive trials, but controlled and peer-reviewed. Subsequent development moved to PT-141, so MT-II-specific erectile dysfunction trial development was never completed.

Melanocytic Nevi Research — The Key Safety Signal

The most clinically important independent research on MT-II safety concerns melanocytic nevi (moles). Multiple case series and cohort studies in the dermatology literature have documented that MT-II use is associated with darkening of existing melanocytic nevi, development of new nevi, and in some reports, atypical or dysplastic changes in nevi. Nevi with atypical features are a recognized risk factor for melanoma development. This signal — first documented in case reports and then investigated more systematically — is the primary reason dermatologists and oncologists express concern about MT-II use and represents the most significant unresolved safety question. The causal relationship between MT-II-induced MC1R activation and melanoma initiation has not been established, but the mechanistic pathway (MC1R activation → melanocyte proliferation → potential for malignant transformation in susceptible cells) is biologically plausible and cannot be dismissed.

---

Common Claims versus Current Evidence

---

Safety, Risks, and Limitations

MT-II requires a more thorough safety discussion than most compounds on this site. The risks are real, they are mechanistically explained, and they include a meaningful unresolved signal that should factor into any research decision.

Nausea and Facial Flushing (Common, Predictable)

Nausea occurs in the majority of users at doses sufficient for tanning or sexual effects. It is mediated by MC4R activation in the area postrema (the brain’s chemoreceptor trigger zone for vomiting). Facial flushing and warmth are mediated by MC4R-driven autonomic vasodilation. Both effects are dose-dependent, typically begin 20–40 minutes after injection, peak at 1–2 hours, and resolve within 4–6 hours. Anti-nausea pretreatment (ondansetron) is commonly used in the self-experimentation community to reduce this side effect. The nausea is unpleasant but not in itself dangerous; the flushing represents real cardiovascular activity (transient blood pressure changes and heart rate increases have been documented) that warrants caution in individuals with cardiovascular disease.

Melanocytic Nevi Changes — The Primary Safety Concern

This is the most clinically serious documented safety signal associated with MT-II use. Multiple case reports and case series in peer-reviewed dermatology journals have documented: darkening of pre-existing melanocytic nevi, development of new melanocytic nevi, and in some cases, new nevi with atypical or dysplastic features. Atypical melanocytic nevi are a recognized independent risk factor for melanoma. Two published case reports document melanoma diagnosis in individuals with recent MT-II use, though causality cannot be established from case reports — confounders including UV history and genetic predisposition cannot be excluded.

The mechanistic pathway for concern is coherent: MC1R activation drives melanocyte proliferation and melanogenesis. In individuals who have pre-malignant melanocytes or who carry genetic variants associated with increased melanoma risk (CDKN2A mutations, multiple atypical nevi syndrome), additional proliferative stimulation of the melanocyte population through exogenous MC1R agonism is a theoretically meaningful additional risk. This is not a confirmed causal relationship — it is a biologically plausible signal documented in case reports that has not been adequately studied in a controlled cohort. But it cannot be dismissed as theoretical noise, and it represents a meaningful reason for dermatological monitoring during MT-II use and a contraindication in individuals with high-risk nevus profiles or melanoma family history.

Cardiovascular Activity

MT-II produces transient cardiovascular effects — transient increases in blood pressure and heart rate have been documented in Phase I studies. These are MC4R-mediated autonomic effects. In the PT-141 development program, transient hypertension was significant enough to trigger FDA guidance requiring measurement of blood pressure before each dose. MT-II carries the same pharmacological risk. For healthy individuals, these transient effects are likely clinically insignificant. For anyone with hypertension, cardiovascular disease, or conditions where transient blood pressure elevation carries risk, this is a meaningful consideration.

Unregulated Sourcing

MT-II is sold by research peptide suppliers without GMP manufacturing requirements. Independent testing of MT-II products from the grey market has documented cases of incorrect peptide sequence, underdosing, overdosing, and contamination. The “nasal tanning spray” market — which sells MT-II solutions for intranasal use without prescription — includes products of particularly variable quality, often with undisclosed ingredients and no certificate of analysis. This is not a pharmacological risk of MT-II itself; it is a practical risk of obtaining it outside a pharmaceutical supply chain. Bacteriostatic water for injection is the correct reconstitution medium for injectable use. Vials from unverified sources should be verified by independent certificate of analysis before use.

Prolonged Erection Risk

The original clinical event that redirected MT-II research involved an eight-hour erection requiring medical treatment. Priapism — prolonged, painful erection not associated with sexual stimulation — is a medical emergency that can result in permanent erectile dysfunction if untreated. This is a dose-dependent risk. At therapeutic doses used in the Wessells ED studies, erections were typically 2–4 hours. At higher doses used for tanning (which are generally higher than sexual effect doses), the risk increases. Anyone using MT-II should understand the priapism risk, use the lowest effective dose, and have a plan for medical treatment if required.

---

Legal and Regulatory Status

MT-II is not FDA-approved for any indication, is not legally sold as a drug in the United States, and has no approved IND (investigational new drug) application currently active for new clinical studies. It is sold by research chemical suppliers as a research peptide. Its import, sale, and use for human administration occupies a grey zone that varies by jurisdiction. In the UK and Australia, it is a prescription-only medicine; obtaining or supplying it without a prescription is illegal. The EU and US regulatory positions treat it as an unapproved drug substance when marketed for human use.

The “nasal tanning spray” grey market sells MT-II under cosmetic or research product framing to avoid drug classification. These products are widely available online and at some beauty salons in certain countries. The regulatory and quality control situation for these products is poor. WADA: MT-II is not currently on the prohibited list.

---

Delivery Considerations

Subcutaneous injection is the route used in published clinical trials and provides the most predictable pharmacokinetics. Typical tanning loading doses in the research literature were 0.025 mg/kg SC, with the Dorr study using doses in the 0.01–0.1 mg/kg range. The self-experimentation community typically uses fixed doses of 0.5–1.0 mg SC for initial tanning loading, with lower doses (0.25–0.5 mg) used for maintenance. Nausea correlates with dose — starting at the lower end of the range and titrating upward reduces the intensity of initial side effects.

Intranasal administration is widely used through the grey market “nasal tan” spray category. Nasal bioavailability for peptides is variable and generally lower than SC injection — typically 10–40% bioavailability for small peptides via nasal mucosa. This means intranasal doses must be higher to achieve equivalent systemic exposure, but the absorption is slower and less predictable. The appeal of intranasal use is avoidance of injection; the practical limitations are dose uncertainty and product quality concerns with the available grey market products.

Reconstitution: Bacteriostatic water for injection (BWI) is the correct diluent. Standard reconstitution is typically 1 mg lyophilized peptide in 1 mL BWI for a 1 mg/mL solution, allowing dose adjustment by volume. Store reconstituted vials refrigerated at 2–8°C; protect from light; use within 4 weeks of reconstitution.

---

Delivery Routes in Self-Experimentation Communities

The self-experimentation community using MT-II divides broadly into two use patterns: cosmetic tanning (typically lower doses, loading over 1–2 weeks then maintenance), and combined tanning/sexual effect use (often at similar or slightly higher doses given the sexual effects occur in the same dose range as tanning). Anti-nausea pretreatment with ondansetron (Zofran, 4 mg oral 30 minutes before injection) is widely practiced and considered to meaningfully reduce nausea frequency. Dermatological monitoring — annual full-body skin examination with a dermatologist familiar with MT-II use — is the appropriate standard for ongoing users given the nevi change signal, but adherence to this standard in the community is low.

---

Frequently Asked Questions

---

Related Compounds: How Melanotan II Compares

Melanotan II sits at the center of the melanocortin compound family — the parent from which two FDA-approved drugs were derived. Understanding MT-II requires understanding how it relates to those derived compounds and to the endogenous melanocortin system. The table below shows all compounds in the Tanning & Melanocortin cluster. For the Sexual Health crossover context — particularly PT-141’s relationship to MT-II — see the PT-141 (Bremelanotide): Research Overview.

---

Summary and Key Takeaways

• Melanotan II is a synthetic, cyclic, non-selective melanocortin receptor agonist derived from alpha-MSH. It activates MC1R (tanning), MC3R and MC4R (libido, appetite suppression), and MC5R (exocrine). The simultaneous activation of all these receptors is the source of both its appeal and its risk profile.
• The tanning mechanism is well-characterized: MC1R activation → cAMP → PKA → CREB → MITF → tyrosinase → eumelanin synthesis. This is the same pathway natural UV-driven tanning uses, triggered pharmacologically rather than by UV damage. The tanning effect is real and documented.
• The sexual arousal mechanism — MC3R/MC4R activation in the hypothalamus and limbic system — is equally well-characterized and is the direct pharmacological basis for PT-141 (bremelanotide), which is FDA-approved for HSDD in women. The sexual effect of MT-II is the same mechanism, without the selectivity engineering that makes PT-141 a cleaner drug candidate.
• Afamelanotide (FDA-approved for EPP) and PT-141 (FDA-approved for HSDD) are the refined descendants of MT-II research — each selecting one part of MT-II’s pharmacology and eliminating the rest. They represent what MT-II could have become if developed through the full clinical pathway for a specific indication.
• Evidence tier: Preclinical/Research Only for most indications — early Phase I human data for tanning and erectile effects; no Phase II or III trials completed; never FDA-submitted for any indication.
• Safety concerns are real and ranked: (1) Melanocytic nevi changes including potential dysplasia — the most serious unresolved signal, contraindicated in high melanoma risk individuals; (2) Cardiovascular effects (transient BP/HR changes) — relevant for those with cardiovascular disease; (3) Priapism risk — medical emergency protocol should be understood before use; (4) Nausea and flushing — predictable, dose-dependent, manageable with antiemetics; (5) Unregulated sourcing — independent CoA verification essential.
• WADA: not prohibited. Regulatory status: not approved anywhere for tanning or sexual indications; grey market research chemical; prescription-only in UK and Australia.
• For people who want the tanning effect specifically: afamelanotide (Scenesse) is the approved, monitored option — but only accessible for EPP. For people who want the sexual arousal effect specifically: PT-141 is the approved, monitored option — accessible by prescription for women with HSDD and off-label in men.

---

Selected References and Key Studies

1. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–84. PMID 8649208 — primary Phase I human tanning trial; original documentation of sexual side effects
2. Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74–9. PMID 11035394
3. Wessells H, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 1998;52(6):1007–12. PMID 9836546
4. Hruby VJ, et al. Cyclic lactam analogues of alpha-melanotropin and their relationship to the pigmentation response. Biochem Biophys Res Commun. 1987;146(1):206–12. PMID 3606589 — foundational MT-II synthesis and characterization
5. Langan EA, et al. Melanotan II: an unlicensed tanning drug with potentially life-threatening side effects. BMJ. 2009;338:b566. PMID 19213780 — case series on melanocytic nevi changes; clinical safety signal documentation
6. Brennan R, et al. Tanning drugs: use and health risks. Int J Drug Policy. 2014;25(1):51–7. PMID 23707291
7. Catania A. Melanocortins in the treatment of sepsis and inflammatory disorders. Eur J Pharmacol. 2007;571(2-3):252–62. — melanocortin receptor system review
8. King SH, et al. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098–106. PMID 17584130

---

Further Reading

• Tanning & Melanocortin Research Cluster — Peptidings.com
• Afamelanotide (Scenesse): Research Overview — Peptidings.com — the FDA-approved MC1R-selective tanning compound derived from MT-II research
• PT-141 (Bremelanotide): Research Overview — Peptidings.com — the FDA-approved MC3R/MC4R-selective sexual arousal compound; Sexual Health cluster cross-reference
• PubMed: Melanotan II Research
• Evidence Levels Explained — Peptidings.com
• How to Reconstitute Lyophilized Peptides — Peptidings.com

---